Cencora
COR
$324.93
+1.26%
Cencora, Inc. is a leading pharmaceutical wholesaler operating within the healthcare sector, specifically in the Medical - Distribution industry. The company's core business involves sourcing and distributing branded, generic, and specialty pharmaceutical products to a vast network of pharmacies, hospital networks, and healthcare providers, and it holds a dominant market position as one of three major players controlling over 90% of the US pharmaceutical wholesale market. The current investor narrative is shaped by its strategic expansion into international markets, notably through the acquisition of Alliance Healthcare in Europe, and the ongoing integration and performance of its ancillary services like global specialty drug logistics and animal health distribution, which are key drivers for diversification and growth beyond its traditional low-margin wholesale operations.…
COR
Cencora
$324.93
COR 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cencora's 12-month outlook, with a consensus price target around $422.41 and implied upside of +30.0% versus the current price.
Average Target
$422.41
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$260 - $422
Analyst target range
Analyst coverage for Cencora is limited, with only 5 analysts providing estimates, which is relatively sparse for a company of its market cap and suggests it may be under-followed compared to larger peers. The consensus sentiment, based on recent institutional ratings, is overwhelmingly bullish, with firms like Barclays, Wells Fargo, JP Morgan, and Morgan Stanley maintaining or upgrading to 'Overweight' or 'Buy' ratings, though a precise average target price and implied upside cannot be calculated from the provided data. The wide range in analyst estimates for future EPS ($26.94 to $28.01) and revenue ($472.63B to $486.98B) indicates a moderate level of uncertainty regarding the company's precise growth trajectory, while the recent pattern of upgrades (e.g., Morgan Stanley and Jefferies in early 2026) signals strengthening conviction in the company's near-term prospects following its quarterly results.
COR Technical Analysis
The stock is in a sustained uptrend over the past year, evidenced by a 1-year price change of +16.20%, but is currently experiencing a significant pullback from its highs. With a current price of $324.80, the stock is trading at approximately 86% of its 52-week range ($267.40 to $377.54), indicating it has retreated meaningfully from its peak but remains well above its annual low, suggesting a potential consolidation phase after a strong run. Recent momentum has turned sharply negative, with the stock down -12.56% over the past month and -4.15% over the past three months, a stark divergence from the positive 1-year trend that signals a corrective phase, likely driven by broader market weakness or profit-taking after the stock's previous ascent towards its 52-week high. Key technical support is anchored at the 52-week low of $267.40, while immediate resistance sits near the recent highs around $377.54; a sustained break below the $300 level could signal a deeper correction towards support, while the stock's beta of 0.718 indicates it has been about 28% less volatile than the broader market, which may provide some relative downside cushion during turbulent periods.
Beta
0.72
0.72x market volatility
Max Drawdown
-17.3%
Largest decline past year
52-Week Range
$269-$378
Price range past year
Annual Return
+18.3%
Cumulative gain past year
| Period | COR Return | S&P 500 |
|---|---|---|
| 1m | -10.2% | -0.3% |
| 3m | -3.2% | -2.0% |
| 6m | +2.2% | +3.5% |
| 1y | +18.3% | +36.2% |
| ytd | -4.1% | -0.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
COR Fundamental Analysis
Revenue growth remains positive but has shown some deceleration; the most recent quarterly revenue (Q1 2026) was $85.93 billion, representing a year-over-year growth of 5.45%, which is a slowdown from the double-digit growth rates seen in prior quarters like Q2 2025 (revenue of $75.45 billion with a higher base). The company's profitability is stable but operates on razor-thin margins characteristic of the distribution industry, with a net income of $559.65 million in the latest quarter yielding a net margin of just 0.65%, and a gross margin of 3.27% which has remained relatively consistent, indicating effective cost management in a low-margin business. The balance sheet shows significant leverage with a debt-to-equity ratio of 7.13, which is high and typical for capital-intensive distributors, but this is offset by robust cash generation, with trailing twelve-month free cash flow of $3.61 billion providing ample internal funding for operations and debt service, though the current ratio of 0.90 suggests a tight liquidity position relative to short-term obligations.
Quarterly Revenue
$85.9B
2025-12
Revenue YoY Growth
+0.05%
YoY Comparison
Gross Margin
+0.03%
Latest Quarter
Free Cash Flow
$3.6B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is COR Overvalued?
Given the company's consistent positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock currently trades at a trailing PE of 38.98x, which is significantly higher than its forward PE of 16.54x, indicating the market is pricing in substantial earnings growth expectations for the coming year. Compared to typical industry averages for medical distributors, which often trade at lower multiples due to their low-growth, high-volume model, Cencora's trailing PE appears at a premium, though this may be justified by its market-leading position, international expansion, and higher-margin service segments like specialty logistics. Historically, the stock's own trailing PE has fluctuated widely, as seen in the historical ratios data ranging from negative figures during loss-making quarters to over 3300x during periods of minimal earnings; the current level of 38.98x is above the more normalized recent historical range (e.g., 21-30x in 2025), suggesting the market is currently valuing the stock optimistically relative to its own history, potentially reflecting confidence in future earnings acceleration.
PE
39.0x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -45x~3303x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.9x
Enterprise Value Multiple